- Home
- FORA vs CGTX Comparison
FORA vs CGTX Comparison
Compare FORA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- CGTX
- Stock Information
- Founded
- FORA 2014
- CGTX 2007
- Country
- FORA United States
- CGTX United States
- Employees
- FORA 37
- CGTX N/A
- Industry
- FORA Computer Software: Prepackaged Software
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- CGTX Health Care
- Exchange
- FORA Nasdaq
- CGTX Nasdaq
- Market Cap
- FORA 69.4M
- CGTX 53.4M
- IPO Year
- FORA N/A
- CGTX 2021
- Fundamental
- Price
- FORA $2.26
- CGTX $1.49
- Analyst Decision
- FORA Strong Buy
- CGTX Strong Buy
- Analyst Count
- FORA 1
- CGTX 3
- Target Price
- FORA $5.00
- CGTX $2.83
- AVG Volume (30 Days)
- FORA 75.0K
- CGTX 8.1M
- Earning Date
- FORA 11-12-2025
- CGTX 11-12-2025
- Dividend Yield
- FORA N/A
- CGTX N/A
- EPS Growth
- FORA N/A
- CGTX N/A
- EPS
- FORA N/A
- CGTX N/A
- Revenue
- FORA $25,031,040.00
- CGTX N/A
- Revenue This Year
- FORA $47.82
- CGTX N/A
- Revenue Next Year
- FORA $10.11
- CGTX N/A
- P/E Ratio
- FORA N/A
- CGTX N/A
- Revenue Growth
- FORA 18.59
- CGTX N/A
- 52 Week Low
- FORA $1.64
- CGTX $0.22
- 52 Week High
- FORA $4.03
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- FORA 60.82
- CGTX 40.54
- Support Level
- FORA $2.20
- CGTX $1.44
- Resistance Level
- FORA $2.39
- CGTX $2.60
- Average True Range (ATR)
- FORA 0.13
- CGTX 0.29
- MACD
- FORA 0.02
- CGTX -0.19
- Stochastic Oscillator
- FORA 75.00
- CGTX 5.24
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.